<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20240302090726&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;ff=20240302090726&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sat, 02 Mar 2024 14:07:28 +0000</lastbuilddate>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Ischaemic heart disease: prevention, management, mechanisms, and new therapeutic targets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427947/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1;45(9):637-641. doi: 10.1093/eurheartj/ehae114.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427947/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427947</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae114>10.1093/eurheartj/ehae114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427947</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Ischaemic heart disease: prevention, management, mechanisms, and new therapeutic targets</dc:title>
<dc:identifier>pmid:38427947</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae114</dc:identifier>
</item>
<item>
<title>First in man: blocking the false lumen backflow of aortic dissection after thoracic endovascular aortic repair by an off-the-shelf EndoSeal™ system</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427788/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae117. doi: 10.1093/eurheartj/ehae117. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427788/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427788</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae117>10.1093/eurheartj/ehae117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427788</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Yangyang Ge</dc:creator>
<dc:creator>Hongpeng Zhang</dc:creator>
<dc:creator>Wei Guo</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>First in man: blocking the false lumen backflow of aortic dissection after thoracic endovascular aortic repair by an off-the-shelf EndoSeal™ system</dc:title>
<dc:identifier>pmid:38427788</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae117</dc:identifier>
</item>
<item>
<title>First case of symptomatic transthyretin cardiac amyloidosis with rare Tyr78Phe variant, normal left ventricular wall thickness, and no cardiac uptake on scintigraphy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427778/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae120. doi: 10.1093/eurheartj/ehae120. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427778/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427778</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae120>10.1093/eurheartj/ehae120</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427778</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Elsa Beard</dc:creator>
<dc:creator>Claire Bouleti</dc:creator>
<dc:creator>Benjamin Alos</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>First case of symptomatic transthyretin cardiac amyloidosis with rare Tyr78Phe variant, normal left ventricular wall thickness, and no cardiac uptake on scintigraphy</dc:title>
<dc:identifier>pmid:38427778</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae120</dc:identifier>
</item>
<item>
<title>Rheumatoid arthritis and cardiovascular complications during delivery: a United States inpatient analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427130/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Pregnant persons with RA had higher risk of preeclampsia, peripartum cardiomyopathy, arrhythmias, acute kidney injury, and venous thromboembolism during delivery hospitalizations. Furthermore, cardiometabolic risk factors among pregnant individuals with RA rose over this 15-year period.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae108. doi: 10.1093/eurheartj/ehae108. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Persons with rheumatoid arthritis (RA) have an increased risk of obstetric-associated complications, as well as long-term cardiovascular (CV) risk. Hence, the aim was to evaluate the association of RA with acute CV complications during delivery admissions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Data from the National Inpatient Sample (2004-2019) were queried utilizing ICD-9 or ICD-10 codes to identify delivery hospitalizations and a diagnosis of RA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 12 789 722 delivery hospitalizations were identified, of which 0.1% were among persons with RA (n = 11 979). Individuals with RA, vs. those without, were older (median 31 vs. 28 years, P &lt; .01) and had a higher prevalence of chronic hypertension, chronic diabetes, gestational diabetes mellitus, obesity, and dyslipidaemia (P &lt; .01). After adjustment for age, race/ethnicity, comorbidities, insurance, and income, RA remained an independent risk factor for peripartum CV complications including preeclampsia [adjusted odds ratio (aOR) 1.37 (95% confidence interval 1.27-1.47)], peripartum cardiomyopathy [aOR 2.10 (1.11-3.99)], and arrhythmias [aOR 2.00 (1.68-2.38)] compared with no RA. Likewise, the risk of acute kidney injury and venous thromboembolism was higher with RA. An overall increasing trend of obesity, gestational diabetes mellitus, and acute CV complications was also observed among individuals with RA from 2004-2019. For resource utilization, length of stay and cost of hospitalization were higher for deliveries among persons with RA.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Pregnant persons with RA had higher risk of preeclampsia, peripartum cardiomyopathy, arrhythmias, acute kidney injury, and venous thromboembolism during delivery hospitalizations. Furthermore, cardiometabolic risk factors among pregnant individuals with RA rose over this 15-year period.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427130/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427130</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae108>10.1093/eurheartj/ehae108</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427130</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Salman Zahid</dc:creator>
<dc:creator>Mohamed S Mohamed</dc:creator>
<dc:creator>Aardra Rajendran</dc:creator>
<dc:creator>Anum S Minhas</dc:creator>
<dc:creator>Muhammad Zia Khan</dc:creator>
<dc:creator>Noreen T Nazir</dc:creator>
<dc:creator>Anthony J Ocon</dc:creator>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Ijeoma Isiadinso</dc:creator>
<dc:creator>Erin D Michos</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Rheumatoid arthritis and cardiovascular complications during delivery: a United States inpatient analysis</dc:title>
<dc:identifier>pmid:38427130</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae108</dc:identifier>
</item>
<item>
<title>Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The findings confirm the heterogeneous aetiology of childhood cardiomyopathies and show a high frequency of familial disease. Outcomes differed by cardiomyopathy subtype, highlighting a need for disease-specific evaluation and treatment.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae109. doi: 10.1093/eurheartj/ehae109. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Childhood-onset cardiomyopathies are rare and poorly characterized. This study examined the baseline characteristics and 1-year follow-up of children with cardiomyopathy in the first European Cardiomyopathy Registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Prospective data were collected on individuals aged 1-&lt;18 years enrolled in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry (June 2014-December 2016).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 633 individuals aged ≤18 years with hypertrophic [HCM; n = 388 (61.3%)], dilated [DCM; n = 206 (32.5%)], restrictive [RCM; n = 28 (4.4%)], and arrhythmogenic right ventricular cardiomyopathy [ARVC; n = 11 (1.7%)] were enrolled by 23 referral centres in 14 countries. Median age at diagnosis was 4.0 [interquartile range (IQR) 0-10] years, and there was a male predominance [n = 372 (58.8%)] across all subtypes, with the exception of DCM diagnosed &lt;10 years of age; 621 (98.1%) patients were receiving cardiac medication and 80 (12.6%) had an implantable cardioverter-defibrillator. A total of 253 patients (253/535, 47.3%) had familial disease. Genetic testing was performed in 414 (67.8%) patients with a pathogenic or likely pathogenic variant reported in 250 (60.4%). Rare disease phenocopies were reported in 177 patients (28.0%) and were most frequent in patients under 10 years [142 (30.9%) vs. 35 (19.6%); P = .003]. Over a median follow-up of 12.5 months (IQR 11.3-15.3 months), 18 patients (3.3%) died [HCM n = 9 (2.6%), DCM n = 5 (3.0%), RCM n = 4 (16.0%)]. Heart failure events were most frequent in RCM patients (36.0%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The findings confirm the heterogeneous aetiology of childhood cardiomyopathies and show a high frequency of familial disease. Outcomes differed by cardiomyopathy subtype, highlighting a need for disease-specific evaluation and treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427064</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae109>10.1093/eurheartj/ehae109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427064</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Juan Pablo Kaski</dc:creator>
<dc:creator>Gabrielle Norrish</dc:creator>
<dc:creator>Juan Ramon Gimeno Blanes</dc:creator>
<dc:creator>Philippe Charron</dc:creator>
<dc:creator>Perry Elliott</dc:creator>
<dc:creator>Luigi Tavazzi</dc:creator>
<dc:creator>Michal Tendera</dc:creator>
<dc:creator>Cécile Laroche</dc:creator>
<dc:creator>Aldo P Maggioni</dc:creator>
<dc:creator>Anwar Baban</dc:creator>
<dc:creator>Diala Khraiche</dc:creator>
<dc:creator>Lidia Ziolkowska</dc:creator>
<dc:creator>Giuseppe Limongelli</dc:creator>
<dc:creator>Tiina Ojala</dc:creator>
<dc:creator>Matthias Gorenflo</dc:creator>
<dc:creator>Aris Anastasakis</dc:creator>
<dc:creator>Shaimaa Mostafa</dc:creator>
<dc:creator>Alida L P Caforio</dc:creator>
<dc:creator>EORP Paediatric Cardiomyopathy Registry Investigators</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry</dc:title>
<dc:identifier>pmid:38427064</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae109</dc:identifier>
</item>
<item>
<title>Inadvertent intracoronary pacemaker lead implantation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38427041/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae116. doi: 10.1093/eurheartj/ehae116. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38427041/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38427041</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae116>10.1093/eurheartj/ehae116</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38427041</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Tilman Perrin</dc:creator>
<dc:creator>Gerrit Hellige</dc:creator>
<dc:creator>Rolf Vogel</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inadvertent intracoronary pacemaker lead implantation</dc:title>
<dc:identifier>pmid:38427041</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae116</dc:identifier>
</item>
<item>
<title>Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38426911/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae101. doi: 10.1093/eurheartj/ehae101. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine-Gray competing risk models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: 1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6-64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%-5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36-.61; P &lt; .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%-6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P &lt; .001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38426911/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38426911</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae101>10.1093/eurheartj/ehae101</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38426911</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Mikhael F El-Chami</dc:creator>
<dc:creator>Christophe Garweg</dc:creator>
<dc:creator>Nicolas Clementy</dc:creator>
<dc:creator>Faisal Al-Samadi</dc:creator>
<dc:creator>Saverio Iacopino</dc:creator>
<dc:creator>Jose Luis Martinez-Sande</dc:creator>
<dc:creator>Paul R Roberts</dc:creator>
<dc:creator>Claudio Tondo</dc:creator>
<dc:creator>Jens Brock Johansen</dc:creator>
<dc:creator>Xavier Vinolas-Prat</dc:creator>
<dc:creator>Yong-Mei Cha</dc:creator>
<dc:creator>Eric Grubman</dc:creator>
<dc:creator>Pierre Bordachar</dc:creator>
<dc:creator>Kurt Stromberg</dc:creator>
<dc:creator>Dedra H Fagan</dc:creator>
<dc:creator>Jonathan P Piccini</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry</dc:title>
<dc:identifier>pmid:38426911</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae101</dc:identifier>
</item>
<item>
<title>Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38426892/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Ankle BP indices including the ankle SBP and the APPD best predicted PAD and mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae087. doi: 10.1093/eurheartj/ehae087. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Few studies have compared arm and ankle blood pressures (BPs) with regard to peripheral artery disease (PAD) and mortality. These relationships were assessed using data from three large prospective clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Baseline BP indices included arm systolic BP (SBP), diastolic BP (DBP), pulse pressure (arm SBP minus DBP), ankle SBP, ankle-brachial index (ABI, ankle SBP divided by arm SBP), and ankle-pulse pressure difference (APPD, ankle SBP minus arm pulse pressure). These measurements were categorized into four groups using quartiles. The outcomes were PAD (the first occurrence of either peripheral revascularization or lower-limb amputation for vascular disease), the composite of PAD or death, and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 40 747 participants without baseline PAD (age 65.6 years, men 68.3%, diabetes 50.2%) from 53 countries, 1071 (2.6%) developed PAD, and 4955 (12.2%) died during 5 years of follow-up. Incident PAD progressively rose with higher arm BP indices and fell with ankle BP indices. The strongest relationships were noted for ankle BP indices. Compared with people whose ankle BP indices were in the highest fourth, adjusted hazard ratios (95% confidence interval) for each lower fourth were 1.64 (1.31-2.04), 2.59 (2.10-3.20), and 4.23 (3.44-5.21) for ankle SBP; 1.19 (0.95-1.50), 1.66 (1.34-2.05), and 3.34 (2.75-4.06) for ABI; and 1.41 (1.11-1.78), 2.04 (1.64-2.54), and 3.63 (2.96-4.45) for APPD. Similar patterns were observed for mortality. Ankle BP indices provided the highest c-statistics and classification indices in predicting future PAD beyond established risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Ankle BP indices including the ankle SBP and the APPD best predicted PAD and mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38426892/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38426892</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae087>10.1093/eurheartj/ehae087</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38426892</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Kamel Mohammedi</dc:creator>
<dc:creator>Marie Pigeyre</dc:creator>
<dc:creator>Jackie Bosch</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>Hertzel C Gerstein</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Arm and ankle blood pressure indices, and peripheral artery disease, and mortality: a cohort study</dc:title>
<dc:identifier>pmid:38426892</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae087</dc:identifier>
</item>
<item>
<title>Transcatheter treatment of the tricuspid valve: current status and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38426859/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to revise obsolete and misleading perceptions around the right side of the heart. New definitions,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae082. doi: 10.1093/eurheartj/ehae082. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcatheter tricuspid valve interventions (TTVI) are emerging as alternatives to surgery in high-risk patients with isolated or concomitant tricuspid regurgitation. The development of new minimally invasive solutions potentially more adapted to this largely undertreated population of patients, has fuelled the interest for the tricuspid valve. Growing evidence and new concepts have contributed to revise obsolete and misleading perceptions around the right side of the heart. New definitions, classifications, and a better understanding of the disease pathophysiology and phenotypes, as well as their associated patient journeys have profoundly and durably changed the landscape of tricuspid disease. A number of registries and a recent randomized controlled pivotal trial provide preliminary guidance for decision-making. TTVI seem to be very safe and effective in selected patients, although clinical benefits beyond improved quality of life remain to be demonstrated. Even if more efforts are needed, increased disease awareness is gaining momentum in the community and supports the establishment of dedicated expert valve centres. This review is summarizing the achievements in the field and provides perspectives for a less invasive management of a no-more-forgotten disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38426859/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38426859</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae082>10.1093/eurheartj/ehae082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38426859</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Francesco Maisano</dc:creator>
<dc:creator>Rebecca Hahn</dc:creator>
<dc:creator>Paul Sorajja</dc:creator>
<dc:creator>Fabien Praz</dc:creator>
<dc:creator>Philipp Lurz</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transcatheter treatment of the tricuspid valve: current status and perspectives</dc:title>
<dc:identifier>pmid:38426859</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae082</dc:identifier>
</item>
<item>
<title>Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38426727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The incidence of myocardial infarction and stroke has halved in patients with kidney failure over the past 20 years but remains significantly higher than in the general population. Despite improvements in treatment and outcomes, the prognosis of these patients following myocardial infarction and stroke remains poor.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 1:ehae080. doi: 10.1093/eurheartj/ehae080. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Patients with kidney failure have a higher risk of cardiovascular disease compared with the general population. Whilst temporal trends of myocardial infarction and stroke are declining in the general population, these have not been evaluated in patients with kidney failure. This study aimed to describe national trends in the incidence, treatment, and outcomes of myocardial infarction and stroke in patients with kidney failure (i.e. on dialysis or with a kidney transplant) over a 20-year period, stratified by age and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this retrospective national data linkage study, all patients with kidney failure in Scotland (UK) receiving kidney replacement therapy between January 1996 and December 2016 were linked to national hospitalization, prescribing, and death records. The primary outcomes were the incidence of myocardial infarction and stroke, and subsequent cardiovascular death. Generalized additive models were constructed to estimate age-standardized, sex-stratified incidence rates and trends in cardiovascular and all-cause death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Amongst 16 050 patients with kidney failure [52 (SD 15) years; 41.5% women], there were 1992 [66 (SD 12) years; 34.8% women] and 996 [65 (SD 13) years; 45.1% women] incident myocardial infarctions and strokes, respectively, between January 1996 and December 2016. During this period, the age-standardized incidence of myocardial infarction per 100 000 decreased in men {from 4376 [95% confidence interval (CI) 3998-4785] to 1835 (95% CI 1692-1988)} and women [from 3268 (95% CI 2982-3593) to 1369 (95% CI 1257-1491)]. Similarly, the age-standardized incidence of stroke per 100 000 also decreased in men [from 1978 (95% CI 1795-2175) to 799 (95% CI 729-875)] and women [from 2234 (95% CI 2031-2468) to 903 (95% CI 824-990)]. Compared with the general population, the incidence of myocardial infarction was four- to eight-fold higher in patients with kidney failure, whilst for stroke it was two- to four-fold higher. The use of evidence-based cardioprotective treatment increased over the study period, and the predicted probability of cardiovascular death within 1 year of myocardial infarction for a 66-year-old patient with kidney failure (mean age of the cohort) fell in men (76.6% to 38.6%) and women (76.8% to 38.8%), and also decreased in both sexes following stroke (men, from 63.5% to 41.4%; women, from 67.6% to 45.8%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The incidence of myocardial infarction and stroke has halved in patients with kidney failure over the past 20 years but remains significantly higher than in the general population. Despite improvements in treatment and outcomes, the prognosis of these patients following myocardial infarction and stroke remains poor.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38426727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38426727</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae080>10.1093/eurheartj/ehae080</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38426727</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Peter J Gallacher</dc:creator>
<dc:creator>David Yeung</dc:creator>
<dc:creator>Samira Bell</dc:creator>
<dc:creator>Anoop S V Shah</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Neeraj Dhaun</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Kidney replacement therapy: trends in incidence, treatment, and outcomes of myocardial infarction and stroke in a nationwide Scottish study</dc:title>
<dc:identifier>pmid:38426727</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae080</dc:identifier>
</item>
<item>
<title>MBNL1 Regulates Programmed Postnatal Switching Between Regenerative and Differentiated Cardiac States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38426339/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Here, MBNL1 was identified as an essential regulator of cardiomyocyte differentiated states, their developmental switch from hyperplastic to hypertrophic growth, and their regenerative potential through controlling an entire maturation program by stabilizing adult myocyte mRNAs during postnatal development and throughout adulthood. Targeting loss of cardiomyocyte maturity and downregulation of cell cycle inhibitors through MBNL1 deletion was not sufficient to promote adult...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Mar 1. doi: 10.1161/CIRCULATIONAHA.123.066860. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Discovering determinants of cardiomyocyte maturity is critical for deeply understanding the maintenance of differentiated states and potentially reawakening endogenous regenerative programs in adult mammalian hearts as a therapeutic strategy. Forced dedifferentiation paired with oncogene expression is sufficient to drive cardiac regeneration, but elucidation of endogenous developmental regulators of the switch between regenerative and mature cardiomyocyte cell states is necessary for optimal design of regenerative approaches for heart disease. MBNL1 (muscleblind-like 1) regulates fibroblast, thymocyte, and erythroid differentiation and proliferation. Hence, we examined whether MBNL1 promotes and maintains mature cardiomyocyte states while antagonizing cardiomyocyte proliferation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: MBNL1 gain- and loss-of-function mouse models were studied at several developmental time points and in surgical models of heart regeneration. Multi-omics approaches were combined with biochemical, histological, and in vitro assays to determine the mechanisms through which MBNL1 exerts its effects.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: MBNL1 is coexpressed with a maturation-association genetic program in the heart and is regulated by the MEIS1/calcineurin signaling axis. Targeted MBNL1 overexpression early in development prematurely transitioned cardiomyocytes to hypertrophic growth, hypoplasia, and dysfunction, whereas loss of MBNL1 function increased cardiomyocyte cell cycle entry and proliferation through altered cell cycle inhibitor transcript stability. Moreover, MBNL1-dependent stabilization of estrogen-related receptor signaling was essential for maintaining cardiomyocyte maturity in adult myocytes. In accordance with these data, modulating MBNL1 dose tuned the temporal window of neonatal cardiac regeneration, where increased MBNL1 expression arrested myocyte proliferation and regeneration and MBNL1 deletion promoted regenerative states with prolonged myocyte proliferation. However, MBNL1 deficiency was insufficient to promote regeneration in the adult heart because of cell cycle checkpoint activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Here, MBNL1 was identified as an essential regulator of cardiomyocyte differentiated states, their developmental switch from hyperplastic to hypertrophic growth, and their regenerative potential through controlling an entire maturation program by stabilizing adult myocyte mRNAs during postnatal development and throughout adulthood. Targeting loss of cardiomyocyte maturity and downregulation of cell cycle inhibitors through MBNL1 deletion was not sufficient to promote adult regeneration.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38426339/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38426339</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066860>10.1161/CIRCULATIONAHA.123.066860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38426339</guid>
<pubDate>Fri, 01 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Logan R J Bailey</dc:creator>
<dc:creator>Darrian Bugg</dc:creator>
<dc:creator>Isabella M Reichardt</dc:creator>
<dc:creator>C Dessirée Ortaç</dc:creator>
<dc:creator>Abigail Nagle</dc:creator>
<dc:creator>Jagadambika Gunaje</dc:creator>
<dc:creator>Amy Martinson</dc:creator>
<dc:creator>Richard Johnson</dc:creator>
<dc:creator>Michael J MacCoss</dc:creator>
<dc:creator>Tomoya Sakamoto</dc:creator>
<dc:creator>Daniel P Kelly</dc:creator>
<dc:creator>Michael Regnier</dc:creator>
<dc:creator>Jennifer M Davis</dc:creator>
<dc:date>2024-03-01</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>MBNL1 Regulates Programmed Postnatal Switching Between Regenerative and Differentiated Cardiac States</dc:title>
<dc:identifier>pmid:38426339</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066860</dc:identifier>
</item>
<item>
<title>Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):502-504. doi: 10.1161/CIRCRESAHA.124.324164. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422183</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324164>10.1161/CIRCRESAHA.124.324164</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422183</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Felix G Liang</dc:creator>
<dc:creator>Javid Moslehi</dc:creator>
<dc:creator>Richard N Kitsis</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response</dc:title>
<dc:identifier>pmid:38422183</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324164</dc:identifier>
</item>
<item>
<title>B-Cell Immune Checkpoints Come of Age in Cardio-oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):569-571. doi: 10.1161/CIRCRESAHA.124.324243. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422182</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324243>10.1161/CIRCRESAHA.124.324243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422182</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Alan Gutierrez</dc:creator>
<dc:creator>Javid J Moslehi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>B-Cell Immune Checkpoints Come of Age in Cardio-oncology</dc:title>
<dc:identifier>pmid:38422182</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324243</dc:identifier>
</item>
<item>
<title>Correction to: Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):e16. doi: 10.1161/RES.0000000000000660. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422181</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000660>10.1161/RES.0000000000000660</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422181</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</dc:title>
<dc:identifier>pmid:38422181</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000660</dc:identifier>
</item>
<item>
<title>Unveiling the Spatiotemporal Diversity of the Endothelium in Development: A Multi-Omics Approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):547-549. doi: 10.1161/CIRCRESAHA.124.324328. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422180</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324328>10.1161/CIRCRESAHA.124.324328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422180</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Roy Jung</dc:creator>
<dc:creator>Chinmay M Trivedi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Unveiling the Spatiotemporal Diversity of the Endothelium in Development: A Multi-Omics Approach</dc:title>
<dc:identifier>pmid:38422180</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324328</dc:identifier>
</item>
<item>
<title>Early Career Research Support From the American Heart Association: to the Second Century and Beyond</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):478-481. doi: 10.1161/CIRCRESAHA.123.323060. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422179</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323060>10.1161/CIRCRESAHA.123.323060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422179</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jessica Pfleger</dc:creator>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Early Career Research Support From the American Heart Association: to the Second Century and Beyond</dc:title>
<dc:identifier>pmid:38422179</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323060</dc:identifier>
</item>
<item>
<title>Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):526-528. doi: 10.1161/CIRCRESAHA.123.323945. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422178</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323945>10.1161/CIRCRESAHA.123.323945</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422178</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Mathias Mericskay</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart</dc:title>
<dc:identifier>pmid:38422178</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323945</dc:identifier>
</item>
<item>
<title>Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):505-525. doi: 10.1161/CIRCRESAHA.123.322910. Epub 2024 Feb 7.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronic overconsumption of lipids followed by their excessive accumulation in the heart leads to cardiomyopathy. The cause of lipid-induced cardiomyopathy involves a pivotal role for the proton-pump vacuolar-type H<sup>+</sup>-ATPase (v-ATPase), which acidifies endosomes, and for lipid-transporter CD36, which is stored in acidified endosomes. During lipid overexposure, an increased influx of lipids into cardiomyocytes is sensed by v-ATPase, which then disassembles, causing endosomal de-acidification and expulsion of stored CD36 from the endosomes toward the sarcolemma. Once at the sarcolemma, CD36 not only increases lipid uptake but also interacts with inflammatory receptor TLR4 (Toll-like receptor 4), together resulting in lipid-induced insulin resistance, inflammation, fibrosis, and cardiac dysfunction. Strategies inducing v-ATPase reassembly, that is, to achieve CD36 reinternalization, may correct these maladaptive alterations. For this, we used NAD<sup>+</sup> (nicotinamide adenine dinucleotide)-precursor nicotinamide mononucleotide (NMN), inducing v-ATPase reassembly by stimulating glycolytic enzymes to bind to v-ATPase.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Rats/mice on cardiomyopathy-inducing high-fat diets were supplemented with NMN and for comparison with a cocktail of lysine/leucine/arginine (mTORC1 [mechanistic target of rapamycin complex 1]-mediated v-ATPase reassembly). We used the following methods: RNA sequencing, mRNA/protein expression analysis, immunofluorescence microscopy, (co)immunoprecipitation/proximity ligation assay (v-ATPase assembly), myocellular uptake of [<sup>3</sup>H]chloroquine (endosomal pH), and [<sup>14</sup>C]palmitate, targeted lipidomics, and echocardiography. To confirm the involvement of v-ATPase in the beneficial effects of both supplementations, mTORC1/v-ATPase inhibitors (rapamycin/bafilomycin A1) were administered. Additionally, 2 heart-specific v-ATPase-knockout mouse models (subunits V<sub>1</sub>G1/V<sub>0</sub>d2) were subjected to these measurements. Mechanisms were confirmed in pharmacologically/genetically manipulated cardiomyocyte models of lipid overload.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NMN successfully preserved endosomal acidification during myocardial lipid overload by maintaining v-ATPase activity and subsequently prevented CD36-mediated lipid accumulation, CD36-TLR4 interaction toward inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance. Lipidomics revealed C18:1-enriched diacylglycerols as lipid class prominently increased by high-fat diet and subsequently reversed/preserved by lysine/leucine/arginine/NMN treatment. Studies with mTORC1/v-ATPase inhibitors and heart-specific v-ATPase-knockout mice further confirmed the pivotal roles of v-ATPase in these beneficial actions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422177</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322910>10.1161/CIRCRESAHA.123.322910</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422177</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Shujin Wang</dc:creator>
<dc:creator>Yinying Han</dc:creator>
<dc:creator>Ruimin Liu</dc:creator>
<dc:creator>Mengqian Hou</dc:creator>
<dc:creator>Dietbert Neumann</dc:creator>
<dc:creator>Jun Zhang</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Yumeng Li</dc:creator>
<dc:creator>Xueya Zhao</dc:creator>
<dc:creator>Francesco Schianchi</dc:creator>
<dc:creator>Chao Dai</dc:creator>
<dc:creator>Lizhong Liu</dc:creator>
<dc:creator>Miranda Nabben</dc:creator>
<dc:creator>Jan F C Glatz</dc:creator>
<dc:creator>Xin Wu</dc:creator>
<dc:creator>Xifeng Lu</dc:creator>
<dc:creator>Xi Li</dc:creator>
<dc:creator>Joost J F P Luiken</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis</dc:title>
<dc:identifier>pmid:38422177</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322910</dc:identifier>
</item>
<item>
<title>Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>The crosstalk of the heart with distant organs such as the lung, liver, gut, and kidney has been intensively approached lately. The kidney is involved in (1) the production of systemic relevant products, such as renin, as part of the most essential vasoregulatory system of the human body, and (2) in the clearance of metabolites with systemic and organ effects. Metabolic residue accumulation during kidney dysfunction is known to determine cardiovascular pathologies such as endothelial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):592-613. doi: 10.1161/CIRCRESAHA.123.324001. Epub 2024 Feb 29.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The crosstalk of the heart with distant organs such as the lung, liver, gut, and kidney has been intensively approached lately. The kidney is involved in (1) the production of systemic relevant products, such as renin, as part of the most essential vasoregulatory system of the human body, and (2) in the clearance of metabolites with systemic and organ effects. Metabolic residue accumulation during kidney dysfunction is known to determine cardiovascular pathologies such as endothelial activation/dysfunction, atherosclerosis, cardiomyocyte apoptosis, cardiac fibrosis, and vascular and valvular calcification, leading to hypertension, arrhythmias, myocardial infarction, and cardiomyopathies. However, this review offers an overview of the uremic metabolites and details their signaling pathways involved in cardiorenal syndrome and the development of heart failure. A holistic view of the metabolites, but more importantly, an exhaustive crosstalk of their known signaling pathways, is important for depicting new therapeutic strategies in the cardiovascular field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422175</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324001>10.1161/CIRCRESAHA.123.324001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422175</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Adelina Curaj</dc:creator>
<dc:creator>Raymond Vanholder</dc:creator>
<dc:creator>Joseph Loscalzo</dc:creator>
<dc:creator>Kaiseng Quach</dc:creator>
<dc:creator>Zhuojun Wu</dc:creator>
<dc:creator>Vera Jankowski</dc:creator>
<dc:creator>Joachim Jankowski</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways</dc:title>
<dc:identifier>pmid:38422175</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324001</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):476-477. doi: 10.1161/RES.0000000000000665. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422174</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000665>10.1161/RES.0000000000000665</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422174</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38422174</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000665</dc:identifier>
</item>
<item>
<title>PIEZO Ion Channels in Cardiovascular Functions and Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240302090726&amp;v=2.18.0.post9+e462414
      <description>The cardiovascular system provides blood supply throughout the body and as such is perpetually applying mechanical forces to cells and tissues. Thus, this system is primed with mechanosensory structures that respond and adapt to changes in mechanical stimuli. Since their discovery in 2010, PIEZO ion channels have dominated the field of mechanobiology. These have been proposed as the long-sought-after mechanosensitive excitatory channels involved in touch and proprioception in mammals. However,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):572-591. doi: 10.1161/CIRCRESAHA.123.322798. Epub 2024 Feb 29.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The cardiovascular system provides blood supply throughout the body and as such is perpetually applying mechanical forces to cells and tissues. Thus, this system is primed with mechanosensory structures that respond and adapt to changes in mechanical stimuli. Since their discovery in 2010, PIEZO ion channels have dominated the field of mechanobiology. These have been proposed as the long-sought-after mechanosensitive excitatory channels involved in touch and proprioception in mammals. However, more and more pieces of evidence point to the importance of PIEZO channels in cardiovascular activities and disease development. PIEZO channel-related cardiac functions include transducing hemodynamic forces in endothelial and vascular cells, red blood cell homeostasis, platelet aggregation, and arterial blood pressure regulation, among others. PIEZO channels contribute to pathological conditions including cardiac hypertrophy and pulmonary hypertension and congenital syndromes such as generalized lymphatic dysplasia and xerocytosis. In this review, we highlight recent advances in understanding the role of PIEZO channels in cardiovascular functions and diseases. Achievements in this quickly expanding field should open a new road for efficient control of PIEZO-related diseases in cardiovascular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240302090726&v=2.18.0.post9+e462414">38422173</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322798>10.1161/CIRCRESAHA.123.322798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422173</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Bertrand Coste</dc:creator>
<dc:creator>Patrick Delmas</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>PIEZO Ion Channels in Cardiovascular Functions and Diseases</dc:title>
<dc:identifier>pmid:38422173</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322798</dc:identifier>
</item>





























</channel>
</rss>